Evidence map›Paper›PMID 34940607›Full record

ReviewMetabolites2021

New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease-Mineral and Bone Disorder.

Maria L Mace, Søren Egstrand, Marya Morevati, Klaus Olgaard, Ewa Lewin

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07193056 (Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07193056 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort

Typeobservational_patient_registrySponsorHerlev HospitalRan2025 to 2055Enrolled1,000ConditionsChronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Disease (CKD), Bone Markers
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Review
  13. Biological Activity of Different Forms of Oxidized Parathyroid Hormone.International journal of molecular sciences · 2022
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Maria L MaceDepartment of Nephrology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
Søren EgstrandDepartment of Nephrology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
Marya MorevatiDepartment of Nephrology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
Klaus OlgaardDepartment of Nephrology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
Ewa LewinDepartment of Nephrology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
University of Copenhagen · DKHerlev Hospital · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease-mineral and bone disorder (CKD-MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular-bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD-MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.

Indexed as

activin Adickkopf-1renal osteodystrophysclerostinTGF-β signalingtissue crosstalkuremic vasculopathyvascular calcificationWnt pathway

Identifiers

PMID34940607
PMCPMC8708186
OpenAlexW4200387665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.